Diphtheria Toxoid / Pertussis, Acellular / Tetanus Toxoid Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Diphtheria Prophylaxis

Booster Immunization (ADACEL):

18 to 64 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Booster Immunization (BOOSTRIX):
18 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Adult Dose for Tetanus Prophylaxis

Booster Immunization (ADACEL):

18 to 64 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Booster Immunization (BOOSTRIX):
18 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Pediatric Dose for Diphtheria Prophylaxis

Booster Immunization (tetanus/diphtheria/pertussis, acel (Tdap) 5 units-2 units-15.5 mcg/0.5 mL ADACEL):

11 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Booster Immunization (tetanus/diphtheria/pertussis, acel (Tdap) 5 units-2 .5units-18.5 mcg/0.5 mL BOOSTRIX):

10 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Pediatric Dose for Tetanus Prophylaxis

Booster Immunization (tetanus/diphtheria/pertussis, acel (Tdap) 5 units-2 units-15.5 mcg/0.5 mL ADACEL):

11 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Booster Immunization (tetanus/diphtheria/pertussis, acel (Tdap) 5 units-2 .5units-18.5 mcg/0.5 mL BOOSTRIX):

10 years or older: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Diphtheria/pertussis, acellular/tetanus is contraindicated if encephalopathy not attributable to another cause developed within 7 days of administration of previous dose.

If a progressive neurologic disorder, uncontrolled epilepsy, or progressive encephalopathy is present, do not administer vaccine until a treatment regimen has been established, the condition stabilized, and the benefit clearly outweighs the risk.

Because intramuscular injections can cause injection site hematoma, diphtheria/pertussis, acellular/tetanus vaccine should not be given to patients with any bleeding disorder, such as thrombocytopenia or hemophilia, or on anticoagulation therapy unless the potential benefit clearly outweighs the risk of administration.

Caution should be exercised when administering diphtheria/pertussis, acellular/tetanus to patients who presented the following symptoms after receiving a previous dose of pertussis vaccine: fever of greater than 40.5 degrees Celsius occurring within 48 hours; collapse or shocklike state (i.e., hypnotic hyporesponsive episode) occurring within 48 hours; persistent, inconsolable crying lasting 3 or more hours occurring within 48 hours, or: seizures with or without fever occurring within 3 days

Epinephrine injection 1:1000 must be immediately available should an acute anaphylactic reaction occur due to any component of the vaccine.

Do not administer this product intravenously or subcutaneously.

Dialysis

Data not available

Other Comments

Administer the vaccine intramuscularly.

Common adverse reactions and all serious reactions that occur during administration in the U.S. should be reported to the U.S. Department of Health and Human Services Vaccine Adverse Event Reporting System. Reporting forms and information regarding the completion of the form can be obtained at 1-800-822-7967.

Hide
(web4)